STOCK TITAN

Accolade, Inc. - ACCD STOCK NEWS

Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.

Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.

The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.

Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.

Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.

Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.

With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.

For more information, visit accolade.com.

Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) to present at 42nd Annual J.P. Morgan Healthcare Conference and 26th Annual Needham Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
conferences
-
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) will release fiscal third quarter 2024 financial results on January 8, 2024, after the market closes. A conference call to review results will be held at 4:30 p.m. E.T. on the same day. Details for listening via telephone and internet, as well as the replay, are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
-
Rhea-AI Summary
Accolade, Inc. (ACCD) to Present at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
conferences
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) announced the repurchase of approximately $76.5 million aggregate principal amount of its outstanding 0.50% Convertible Senior Notes due 2026 for an aggregate cash repurchase price of approximately $65.8 million. The company aims to strengthen its balance sheet and improve its net cash position through this strategic move, positioning itself for long-term financial and strategic success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
buyback
-
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) to Present at Stephen Annual Investment Conference on November 15, 2023. Webcast and replay available at ir.accolade.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
-
Rhea-AI Summary
Accolade (ACCD) Achieves 227% Revenue Growth, Named to Deloitte Technology Fast 500™ List
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
Rhea-AI Summary
Accolade announces findings from employer survey on sentiment and adoption of GLP-1 medications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
-
Rhea-AI Summary
Accolade, Inc. announces strong demand for its solutions and a growing customer base of over 1,000 customers. Financial highlights for the fiscal second quarter show an 11% increase in revenue to $96.9 million and a net loss of $32.8 million, a 29% improvement. Adjusted EBITDA improved by 36% to $(8.8) million. Accolade expects cost reduction measures to lead to profitability in the second half of the year. Forward-looking guidance for the fiscal third quarter includes revenue between $95 million and $97 million and Adjusted EBITDA between $(5) million and $(8) million. For the fiscal year ending February 29, 2024, revenue is expected to be between $410 million and $414 million, with Adjusted EBITDA between $(6) million and $(12) million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.13%
Tags
-
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) to release fiscal Q2 2024 results on October 4, 2023 after market closes. Conference call to review results at 4:30 p.m. E.T. on the same day. Replay available for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
Rhea-AI Summary
Accolade expands care delivery team with new leadership roles
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
none

FAQ

What is the current stock price of Accolade (ACCD)?

The current stock price of Accolade (ACCD) is $3.48 as of December 20, 2024.

What is the market cap of Accolade (ACCD)?

The market cap of Accolade (ACCD) is approximately 271.4M.

What does Accolade, Inc. do?

Accolade, Inc. provides personalized healthcare solutions that integrate virtual primary care, mental health services, expert medical opinions, and care navigation to enhance healthcare experiences and outcomes.

How has Accolade performed financially recently?

Accolade has shown significant financial improvement, including a 227% revenue growth and a substantial reduction in net loss, indicating a strong trajectory toward sustainable growth and profitability.

What is the Trusted Partner Ecosystem?

Launched in 2019, Accolade's Trusted Partner Ecosystem consists of partnerships with leading companies to offer comprehensive healthcare solutions across various categories, including fertility, metabolic health, and behavioral health.

Who are Accolade's key partners?

Accolade partners with companies like Kindbody for fertility services and Noom for weight loss and metabolic health, enhancing their comprehensive healthcare offerings.

What recognition has Accolade received?

Accolade has been recognized by Forbes as one of the nation's 25 most promising companies, by Inc. 500 as the fastest-growing private healthcare company, and by Deloitte Technology Fast 500 for its impressive growth.

What is Accolade's mission?

Accolade's mission is to improve healthcare experiences and outcomes by guiding individuals through the complexities of the healthcare system, leveraging intelligent technology and expert clinical teams.

How does Accolade contribute to healthcare cost reduction?

Accolade reduces healthcare costs by providing enhanced care navigation and advocacy services that improve health outcomes and optimize healthcare utilization.

How does Accolade engage with its members?

Accolade engages with its members through a combination of virtual primary care, personalized health and benefits support, and proactive engagement from their care teams.

What is Accolade's customer satisfaction rating?

Accolade consistently achieves customer satisfaction ratings of over 90%, reflecting their commitment to providing exceptional healthcare experiences.

Where can I find more information about Accolade?

For more information, you can visit Accolade's website at accolade.com.

Accolade, Inc.

Nasdaq:ACCD

ACCD Rankings

ACCD Stock Data

271.41M
77.99M
3.16%
83.54%
4.52%
Health Information Services
Services-business Services, Nec
Link
United States of America
PLYMOUTH MEETING